Kosmonova buran  

http://www.winstonlabs.com/newsandpresentations/pressreleases.html GrB  

technologies for the management of pain.  Our research and development resources are directed toward conditions for which there are no approved prescription medications or those in which approved therapies have limited clinical utility due to suboptimal efficacy, side effects, drug interactions and contraindications.   http://www.winstonlabs.com/productdevelopment/index.html
 

positions in promising market segments by creating novel products and by targeting patient populations with unmet therapeutic needs.

A common feature of our product candidates is the use of an active ingredient which depletes or interferes with the action of a neuroactive transmitter (e.g., substance P (SP), calcitonin gene-related peptide (CGRP), histamine, serotonin), thereby decreasing the ability of sensory fibers or nerve ganglia to transmit or receive sensory stimuli and mediate inflammatory reactions.

Winston's late stage candidates include episodic cluster headache, chronic migraine headache, osteo-and rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. http://www.winstonlabs.com/productdevelopment/index.html  

Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the discovery and development of products for pain management. The Company’s core proprietary technology affects the functioning of certain neurotransmitters that control and mediate pain transmission and inflammation. Based on this technology, the Company is developing products that reduce pain transmission from peripheral receptors along nerve pathways to the brain. The Company focuses on major pain indications such as episodic cluster headache, chronic migraine headache, neuropathic pain syndromes, osteo- and rheumatoid arthritis, and pain and inflammation in inflammatory bowel disease, as well as niche indications which have limited or no products currently available. http://www.winstonlabs.com/about/index.html
 

100 N. Fairway Drive, Suite 134
Vernon Hills, IL 60061
T: (847) 362-8200
F: (847) 362-8394
info@winstonlabs.com
http://www.winstonlabs.com/about/index.html  

Datum Erster Hoch Tief Schluss Stücke Volumen
  31.12.15     0,012     0,012§0,012 0,012 $ 925 11

GrB  

::::::::::::: Keine aktuellen Kursdaten verfügbar ,GrB
 

ISIN: US9756571074  Symbol: WPHM Typ: Aktie
 

::::::::: 0,018 $ 0,00% +0,00 $
In Euro: 0,0164 € | 07.07.16 Nasdaq OTC Other ,GrB  

kein aktueller Kurs verfügbar ,GrB
 

2012  - Winston Pharmaceuticals, Inc. (“Winston”), a specialty
pharmaceutical company focused on developing and commercializing novel pain management
therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant
under the Small Business Innovation Research (SBIR) program supporting the development of
Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia
(PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately
$375,000 will be administered by the National Institute of Neurological Disorders and Stroke
(NINDS). http://www.winstonlabs.com/files/documents/114_winstonlabs_4-9-12.pdf